PALO ALTO, Calif., Sept. 15, 2025 – Kodiak Sciences Inc. (Nasdaq: KOD), a retina-focused biotechnology company, announced new data from its Phase 1b APEX study of KSI-101, reinforcing clinically meaningful vision gains and rapid retinal drying in patients with macular edema secondary to inflammation (MESI). The results were presented at the Retina Society 58th Annual Scientific Meeting in Chicago, underscoring the therapy’s potential to address a significant unmet medical need.
Science Significance
KSI-101 is a bispecific investigational therapy with a novel mechanism of action targeting interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF). By simultaneously inhibiting these two critical pathways, the drug demonstrates robust anti-inflammatory and anti-angiogenic effects.
Patients experienced meaningful improvements in vision as early as Week 4, with more than half of patients at higher dose levels achieving ≥15-letter gain on the ETDRS eye chart. Additionally, retinal fluid resolved in a majority of patients, and by Week 8, over 90% achieved complete retinal dryness.
These outcomes highlight the biological potency and unique mechanism of KSI-101, positioning it as a potentially transformative therapy for MESI and related retinal diseases where no approved intravitreal biologics currently exist.
Regulatory Significance
Advertisement
The encouraging APEX study results build momentum as Kodiak advances two Phase 3 trials, PEAK and PINNACLE, which are actively enrolling patients at the 5 mg and 10 mg dose levels.
The FDA-cleared trials aim to confirm superiority over sham treatments and could pave the way for regulatory filings as early as 2027. If successful, KSI-101 could establish a first-in-class therapeutic option for MESI, a heterogeneous group of retinal disorders caused by inflammation and blood-retinal barrier disruption.
Regulatory approval would also validate Kodiak’s ABC Platform, which integrates protein and chemistry-based approaches to engineer next-generation biologics for ophthalmology.
Business Significance
For Kodiak Sciences, the APEX data mark an important milestone. The company’s pipeline already includes tarcocimab and KSI-501 in Phase 3 for retinal vascular diseases, targeting the multi-billion-dollar anti-VEGF market.
KSI-101 represents an entry into a new “greenfield” market segment for MESI, separate from anti-VEGF treatments. Success here could expand Kodiak’s addressable market significantly, diversifying its revenue base upon commercialization.
The drug’s favorable safety profile, combined with rapid onset of action and broad activity across multiple MESI subtypes, strengthens Kodiak’s competitive position. With topline data readouts expected in late 2026 and early 2027, investors and strategic partners are watching closely.
Patients’ Significance
For patients with MESI, the burden is profound—vision loss, limited treatment options, and poor quality of life. Current therapies such as intraocular steroid implants offer some benefit but are associated with side effects.
KSI-101 delivered a drying effect on par with, or better than, steroid implants—without their associated risks. Patients not only maintained vision but, in many cases, gained meaningful improvements.
The potential for a safe, effective, and long-term therapy could reshape the treatment paradigm, offering hope to individuals suffering from uveitic macular edema, idiopathic macular edema, inflammatory choroidal neovascularization, and other forms of MESI.
Policy Significance
The development of KSI-101 also raises broader healthcare implications. MESI currently represents a high unmet need with no targeted biologics. Regulatory bodies and payers may prioritize therapies like KSI-101 that can reduce hospital visits, preserve vision, and improve quality of life.
From a policy perspective, approval of a dual-action biologic such as KSI-101 could catalyze greater investment in bispecific and protein-engineering platforms, reinforcing innovation pathways in ophthalmology. Moreover, reducing long-term blindness-related costs could align with global public health goals for vision preservation.
Transaction Highlights
Kodiak Sciences presented new data from its Phase 1b APEX study of KSI-101, reinforcing its potential as a bispecific antibody therapy for macular edema secondary to inflammation (MESI). More than half of patients at the 5 mg and 10 mg dose levels achieved a ≥15-letter gain in vision, with improvements seen as early as Week 4. A single dose of KSI-101 led to resolution of intra-retinal and sub-retinal fluid in most patients, with over 90% achieving retinal dryness by Week 8. Across both MESI and diabetic macular edema (DME) cohorts, patients showed meaningful vision and anatomical gains with a favorable safety profile. These findings support the advancement of KSI-101 into Phase 3 PEAK and PINNACLE trials, which are currently enrolling patients at the two highest dose levels (5 mg and 10 mg). Management emphasized that the dual-action mechanism targeting IL-6 and VEGF, combined with rapid retinal drying and broad applicability across inflammatory retinal diseases, positions KSI-101 as a potential first-in-class unifying therapy for MESI.
Source: Kodiak Sciences Inc. Press Release
